372 related articles for article (PubMed ID: 36293518)
1. Role of Intestinal Microbes in Chronic Liver Diseases.
Xu M; Luo K; Li J; Li Y; Zhang Y; Yuan Z; Xu Q; Wu X
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293518
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
3. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
4. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
Nagashimada M; Honda M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
[TBL] [Abstract][Full Text] [Related]
5. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
Lang S; Schnabl B
Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
[TBL] [Abstract][Full Text] [Related]
6. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
[TBL] [Abstract][Full Text] [Related]
7. Impacts of gut microbiota alteration on age-related chronic liver diseases.
Adhikary S; Esmeeta A; Dey A; Banerjee A; Saha B; Gopan P; Duttaroy AK; Pathak S
Dig Liver Dis; 2024 Jan; 56(1):112-122. PubMed ID: 37407321
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the role of gut metabolites in non-alcoholic fatty liver disease.
Ralli T; Saifi Z; Tyagi N; Vidyadhari A; Aeri V; Kohli K
Crit Rev Microbiol; 2023 Nov; 49(6):815-833. PubMed ID: 36394607
[TBL] [Abstract][Full Text] [Related]
9. Intestinal microbiota in liver disease.
Haque TR; Barritt AS
Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
[TBL] [Abstract][Full Text] [Related]
10. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
[TBL] [Abstract][Full Text] [Related]
11. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
Huang W; Kong D
Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
[TBL] [Abstract][Full Text] [Related]
12. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
Das BK
APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
[TBL] [Abstract][Full Text] [Related]
13. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation.
Hendrikx T; Schnabl B
J Intern Med; 2019 Jul; 286(1):32-40. PubMed ID: 30873652
[TBL] [Abstract][Full Text] [Related]
14. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress.
Ferro D; Baratta F; Pastori D; Cocomello N; Colantoni A; Angelico F; Del Ben M
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32927776
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
16. Microbiota, NASH, HCC and the potential role of probiotics.
Brandi G; De Lorenzo S; Candela M; Pantaleo MA; Bellentani S; Tovoli F; Saccoccio G; Biasco G
Carcinogenesis; 2017 Mar; 38(3):231-240. PubMed ID: 28426878
[TBL] [Abstract][Full Text] [Related]
17. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
18. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
19. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage.
Plaza-Díaz J; Solís-Urra P; Rodríguez-Rodríguez F; Olivares-Arancibia J; Navarro-Oliveros M; Abadía-Molina F; Álvarez-Mercado AI
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171747
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]